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Introduction
Malaria remains a devastating global health problem. World-
wide, an estimated 300–500 million people contract malaria
each year, resulting in 1.5–2.7 million deaths annually [1,2].
Because of the increase in global travel to and immigration of
people from areas endemic for malaria, the incidence of
imported cases of malaria in developed countries has risen.
Approximately 10000–30000 travelers from industrialized
countries are expected to contract malaria each year [3]. In
addition, drug-resistant Plasmodium falciparum malaria con-
tinues to spread and at present involves almost all areas of
the world. An increasing number of travelers are exposed to
drug-resistant plasmodia.
Malaria is caused by obligate intraerythrocytic protozoa of the
genus  Plasmodium. Humans can be infected with one (or
more) of the following four species: P. falciparum,  P. vivax,
P. ovale, and P. malariae. Plasmodia are primarily transmitted
by the bite of an infected female Anopheles mosquito, but
infections can also occur through exposure to infected blood
products (transfusion malaria) and by congenital transmission.
In industrialized countries, most cases of malaria occur among
travelers, immigrants, or military personnel returning from areas
endemic for malaria (imported malaria). Exceptionally, local
transmission through mosquitoes occurs (indigenous malaria).
Among patients with unexplained fever or clinical deteriora-
tion who have returned from an endemic area within the past
few years, malaria must be included in the differential diagno-
sis. The evaluation of such cases should always include
taking a comprehensive travel history. Delays in recognition
and appropriate treatment of malaria increase morbidity and
mortality [4]. Here, the clinical manifestations, laboratory find-
ings, diagnosis, and treatment of severe malaria are reviewed.
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Abstract
Malaria represents a medical emergency because it may rapidly progress to complications and death
without prompt and appropriate treatment. Severe malaria is almost exclusively caused by Plasmodium
falciparum. The incidence of imported malaria is increasing and the case fatality rate remains high
despite progress in intensive care and antimalarial treatment. Clinical deterioration usually appears
3–7 days after onset of fever. Complications involve the nervous, respiratory, renal, and/or
hematopoietic systems. Metabolic acidosis and hypoglycemia are common systemic complications.
Intravenous quinine and quinidine are the most widely used drugs in the initial treatment of severe
falciparum malaria, whereas artemisinin derivatives are currently recommended for quinine-resistant
cases. As soon as the patient is clinically stable and able to swallow, oral treatment should be given.
The intravascular volume should be maintained at the lowest level sufficient for adequate systemic
perfusion to prevent development of acute respiratory distress syndrome. Renal replacement therapy
should be initiated early. Exchange blood transfusion has been suggested for the treatment of patients
with severe malaria and high parasitemia. For early diagnosis, it is paramount to consider malaria in
every febrile patient with a history of travel in an area endemic for malaria.
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Characteristics of malaria
Life cycle and morphology
When the infected anopheline mosquito takes a blood meal,
sporozoites are inoculated into the bloodstream. Within an
hour sporozoites enter hepatocytes and begin to divide into
exoerythrocytic merozoites (tissue schizogony). For P. vivax
and  P. ovale, dormant forms called hypnozoites typically
remain quiescent in the liver until a later time; P. falciparum
does not produce hypnozoites. Once merozoites leave the
liver, they invade erythrocytes and develop into early tropho-
zoites, which are ring shaped, vacuolated and uninucleated.
Once the parasite begins to divide, the trophozoites are
called schizonts, consisting of many daughter merozoites
(blood schizogony). Eventually, the infected erythrocytes are
lysed by the merozoites, which subsequently invade other
erythrocytes, starting a new cycle of schizogony. The duration
of each cycle in P. falciparum is about 48 hours. In non-
immune humans, the infection is amplified about 20-fold each
cycle. After several cycles, some of the merozoites develop
into gametocytes, the sexual stage of malaria, which cause no
symptoms, but are infective for mosquitoes [5].
Pre-patent and incubation periods
In nonimmune individuals with P. falciparum infection, the
median pre-patent period (time from sporozoite inoculation to
detectable parasitemia) is 10 days (range 5–10 days), and
the median incubation period (time from sporozoite inocula-
tion to development of symptoms) is 11 days (range
6–14 days). The incubation period may be significantly pro-
longed by the level of immunity acquired through previous
exposures, by antimalarial prophylaxis, or by prior partial treat-
ment, which may mitigate, but not prevent the disease [6].
Most nonimmune travelers develop symptoms of falciparum
malaria within 1 month of departing from a malaria-endemic
area (median 10 days); there have been reports of falciparum
malaria presenting up to 4 years later [7]. For nonfalciparum
malaria the incubation period is usually longer (median 15–16
days), and both P. vivax and  P. ovale  malaria may relapse
months or years after exposure due to the presence of hypno-
zoites in the liver. The longest reported incubation period for
P. vivax is 30 years [7].
Signs and symptoms of malaria
The clinical symptoms of malaria are primarily due to schizont
rupture and destruction of erythrocytes. Malaria can have a
gradual or a fulminant course with nonspecific symptoms.
The presentation of malaria often resembles those of
common viral infections; this may lead to a delay in diagnosis
[8]. The majority of patients experience fever (>92% of
cases), chills (79%), headaches (70%), and diaphoresis
(64%) [9]. Other common symptoms include dizziness,
malaise, myalgia, abdominal pain, nausea, vomiting, mild diar-
rhea, and dry cough. Physical signs include fever, tachycar-
dia, jaundice, pallor, orthostatic hypotension, hepatomegaly,
and splenomegaly. Clinical examination in nonimmune
persons may be completely unremarkable, even without fever.
Severe malaria
Almost all severe forms and deaths from malaria are caused
by P. falciparum. Rarely, P. vivax or P. ovale produce serious
complications, debilitating relapses, and even death [10]. In
1990, the World Health Organization (WHO) established cri-
teria for severe malaria in order to assist future clinical and
epidemiological studies [11]. In 2000, the WHO revised
these criteria to include other clinical manifestations and labo-
ratory values that portend a poor prognosis based on clinical
experience in semi-immune patients (Table 1) [12]. The major
complications of severe malaria include cerebral malaria, pul-
monary edema, acute renal failure, severe anemia, and/or
bleeding. Acidosis and hypoglycemia are the most common
metabolic complications. Any of these complications can
develop rapidly and progress to death within hours or days
[12]. In many patients, several of these complications exist
together or evolve in rapid succession within a few hours. In
clinical practice, patients must be assessed for any of these
signs or symptoms that suggest an increased risk for devel-
oping complications and must be treated immediately. In
various studies risk factors for severe malaria and death
include age greater than 65 years, female sex (especially
when associated with pregnancy), nonimmune status, co-
existing medical conditions, no antimalarial prophylaxis, delay
in treatment, and severity of the illness at admission (coma,
acute renal failure, shock, pulmonary edema, coagulation dis-
orders) [13–15]. In tropical countries with a high transmission
of malaria (hyperendemic areas), severe malaria is predomi-
nantly a disease of young children (1 month to 5 years of age).
In industrialized countries, most life-threatening complications
occur in nonimmune travelers returning from endemic areas.
Severe malaria accounts for approximately 5% of imported
malaria cases (range 1–38%) [9]. The case fatality rate in
returning travelers with falciparum malaria varies from 0.6% to
3.8%, and for severe malaria it may exceed 20%, even when
managed in intensive care units (ICUs) [4].
Laboratory findings
Thrombocytopenia is the most common laboratory abnormality
(60% of cases), followed by hyperbilirubinemia (40%), anemia
(30%), and elevated hepatic aminotransferase levels (25%)
[16]. The leukocyte count is usually normal or low, but neu-
trophilia with a marked increase in band forms (left shift) is
present in the majority of cases. The erythrocyte sedimentation
rate, C-reactive protein, and procalcitonin are almost invariably
elevated. The severity of malaria corresponds to the degree of
the laboratory abnormalities. In one study of travelers who
returned from the tropics, thrombocytopenia and hyperbiliru-
binemia had a positive predictive value of 95% for malaria
[17].
Diagnosis of malaria
Conventional microscopy
Light microscopy of thick and thin stained blood smears
remains the standard method for diagnosing malaria [18].317
Thick smears are 20–40 times more sensitive than thin
smears for screening of Plasmodium parasites, with a detec-
tion limit of 10–50 trophozoites/µl. Thin smears allow one to
identify malaria species (including the diagnosis of mixed
infections), quantify parasitemia, and assess for the presence
of schizonts, gametocytes, and malarial pigment in neu-
trophils and monocytes. The diagnostic accuracy relies on
the quality of the blood smear and experience of laboratory
personnel. Before reporting a negative result, at least 200 oil
immersion visual fields at a magnification of 1000× should be
examined on both thick and thin smears, which has a sensitiv-
ity of 90%. The level of parasitemia may be expressed either
as a percentage of parasitized erythrocytes or as the number
of parasites per microliter of blood. In nonfalciparum malaria,
parasitemia rarely exceeds 2%, whereas it can be consider-
ably higher (>50%) in falciparum malaria. In nonimmune indi-
viduals, hyperparasitemia (>5% parasitemia or >250000
parasites/µl) is generally associated with severe disease [19].
In falciparum malaria, parasitized erythrocytes may be
sequestered in tissue capillaries resulting in a falsely low par-
asite count in the peripheral blood (‘visible’ parasitemia) [7].
In such instances, the developmental stages of the parasite
seen on blood smear may help to assess disease severity
better than parasite count alone. The presence of more
mature parasite forms (>20% of parasites as late tropho-
zoites and schizonts) and of more than 5% of neutrophils
containing malarial pigment indicates more advanced disease
and a worse prognosis [20]. One negative blood smear
makes the diagnosis of malaria very unlikely (especially the
severe form); however, smears should be repeated every
6–12 hours for 48 hours if malaria is still suspected.
Alternative diagnostic methods
Although examination of the thick and thin blood smear is the
‘gold standard’ for diagnosing malaria, important advances
have been made in diagnostic testing, including fluorescence
microscopy of parasite nuclei stained with acridine orange,
rapid dipstick immunoassay, and polymerase chain reaction
assays. Sensitivity and specificity of some of these methods
approach or even exceed those of the thin and thick smear
[21]. Rapid dipstick immunoassays detect species-specific
circulating parasite antigens targeting either the histidine-rich
protein-2 of P. falciparum or a parasite-specific lactate dehy-
drogenase. Although the dipstick tests may enhance diagnos-
tic speed, microscopic examination remains mandatory in
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Table 1
Indicators of severe malaria and poor prognosis
Manifestation Features
Initial World Health Organization criteria from 1990 [11]
Cerebral malaria Unrousable coma not attributable to any other cause, with a Glasgow Coma Scale score ≤9.
Coma should persist for at least 30 min after a generalized convulsion
Severe anemia Hematocrit <15% or hemoglobin <50 g/l in the presence of parasite count >10000/µl
Renal failure Urine output <400 ml/24 hours in adults (<12 ml/kg/24 hours in children) and a serum creatinine
>265 µmol/l (>3.0 mg/dl) despite adequate volume repletion
Pulmonary edema and acute respiratory The acute lung injury score is calculated on the basis of radiographic densities, severity of
distress syndrome hypoxemia, and positive end-expiratory pressure [26]
Hypoglycemia Whole blood glucose concentration <2.2 mmol/l (<40 mg/dl)
Circulatory collapse (algid malaria) Systolic blood pressure <70 mmHg in patients >5 years of age (<50 mmHg in children aged
1–5 years), with cold clammy skin or a core-skin temperature difference >10°C
Abnormal bleeding and/or disseminated Spontaneous bleeding from gums, nose, gastrointestinal tract, or laboratory evidence of
intravascular coagulation disseminated intravascular coagulation
Repeated generalized convulsions ≥3 convulsions observed within 24 hours
Acidemia/acidosis Arterial pH <7.25 or acidosis (plasma bicarbonate <15 mmol/l)
Macroscopic hemoglobinuria Hemolysis not secondary to glucose-6-phosphate dehydrogenase deficiency
Added World Health Organization criteria from 2000 [12]
Impaired consciousness Rousable mental condition
Prostration or weakness
Hyperparasitemia >5% parasitized erythrocytes or >250 000 parasites/µl (in nonimmune individuals)
Hyperpyrexia Core body temperature >40°C
Hyperbilirubinemia Total bilirubin >43 µmol/l (>2.5 mg/dl)318
patients with suspected malaria, because occasionally these
dipstick tests are negative in patients with high parasitemia,
and their sensitivity below 100 parasites/µl is low [22]. Tests
based on polymerase chain reaction for species-specific
Plasmodium genome are more sensitive and specific than are
other tests, detecting as few as 10 parasites/µl blood [23].
Antibody detection has no value in the diagnosis of acute
malaria. It is mainly used for epidemiologic studies.
Complications in patients with severe malaria
Patients with severe malaria should be treated in an ICU.
Should clinical deterioration to severe malaria occur, it usually
develops 3–7 days after fever onset, although there have
been rare reports of nonimmune patients dying within
24 hours of developing symptoms. Severe malaria may
develop even after initial treatment response and complete
clearance of parasitemia due to delayed cytokine release.
Neurologic complications
Cerebral malaria is the most common clinical presentation
and cause of death in adults with severe malaria. The onset
may be dramatic with a generalized convulsion, or gradual
with initial drowsiness and confusion, followed by coma
lasting from several hours to several days. The strict definition
of cerebral malaria requires the presence of P. falciparum
parasitemia and the patient to be unrousable with a Glasgow
Coma Scale score of 9 or less, and other causes (e.g. hypo-
glycemia, bacterial meningitis and viral encephalitis) ruled out
[24]. From a practical standpoint, any alteration in mental
status should be treated as cerebral malaria. A lumbar punc-
ture should be performed to rule out bacterial meningitis. To
distinguish cerebral malaria from transient postictal coma,
unconsciousness should persist for at least 30 min after a
convulsion. The deeper the coma, the worse is the prognosis.
On examination, neurologic abnormalities resemble those of a
diffuse symmetric encephalopathy, similar to a metabolic
encephalopathy. Nuchal rigidity and focal neurologic signs
are rare. Corneal and pupillary reflexes are usually intact. The
plantar responses are extensor in about half of the patients.
Convulsions are usually generalized, with nonspecific abnor-
malities on electroencephalographic examination. Computed
tomography or magnetic resonance imaging often shows evi-
dence of mild cerebral swelling; marked edema or focal
lesions are unusual. Delirium, agitation, and even transient
paranoid psychosis may develop as the patient recovers con-
sciousness. Apart from cerebral malaria, other neurologic
sequelae can occur, such as cranial nerve abnormalities,
extrapyramidal tremor, and ataxia.
Several hypotheses have been proposed to explain the
pathophysiology of cerebral malaria, but none have been
completely satisfactory. The excellent neurologic recovery
argues against ischemia alone being the culprit. Raised
intracranial pressure, at least in nonimmune adults, appears
not to play an important role in the pathogenesis of cerebral
malaria. The mortality of cerebral malaria ranges from 10% to
50% with treatment. Most survivors (>97% adults and >90%
children) have no neurologic abnormalities on hospital dis-
charge [25].
Pulmonary complications
Acute lung injury usually occurs a few days into the disease
course. It may develop rapidly, even after initial response to
antimalarial treatment and clearance of parasitemia. The first
indications of impending pulmonary edema include tachypnea
and dyspnea, followed by hypoxemia and respiratory failure
requiring intubation. Pulmonary edema is usually noncardio-
genic and may progress to acute respiratory distress syn-
drome (ARDS) with an increased pulmonary capillary
permeability [26]. Acute lung injury is defined as the acute
onset of bilateral pulmonary infiltrates with an arterial oxygen
tension/fractional inspired oxygen ratio of 300mmHg or less,
a pulmonary artery wedge pressure of 18mmHg or less, and
no evidence of left atrial hypertension. ARDS is defined as
acute lung injury and an arterial oxygen tension/fractional
inspired oxygen ratio of 200mmHg or less [27]. Volume over-
load and hypoalbuminemia may aggravate pulmonary capillary
leakage. Chest radiograph abnormalities range from confluent
nodules to basilar and/or diffuse bilateral pulmonary infil-
trates. Noncardiogenic pulmonary edema rarely occurs with
P. vivax and P. ovale malaria.
Renal complications
Acute renal failure is usually oliguric (<400ml/day) or anuric
(<50ml/day), rarely nonoliguric, and may require temporary
dialysis [28]. Urine sediment is usually unremarkable. In
severe cases, acute tubular necrosis may develop secondary
to renal ischemia [29]. The term ‘blackwater fever’ refers to
passage of dark red, brown, or black urine secondary to
massive intravascular hemolysis and resulting hemoglobin-
uria. Usually, this condition is transient and not accompanied
by renal failure.
Hypoglycemia
Hypoglycemia is a common feature in patients with severe
malaria. It may be overlooked because all clinical features of
hypoglycemia (anxiety, dyspnea, tachycardia, sweating, coma,
abnormal posturing, generalized convulsions) are also typical
of severe malaria itself. Hypoglycemia may be caused by
quinine- or quinidine-induced hyperinsulinemia, but it may be
found also in patients with normal insulin levels.
Hypotension and shock
Most patients with shock exhibit a low peripheral vascular
resistance and elevated cardiac output. Cardiac pump func-
tion appears remarkably well preserved despite intense
sequestration of parasitized erythrocytes in the microvascula-
ture of the myocardium. Postural hypotension may be sec-
ondary to autonomic dysfunction. Severe hypotension can
develop suddenly, usually with pulmonary edema, metabolic
acidosis, sepsis, and/or massive hemorrhage due to splenic
rupture or from the gastrointestinal tract.
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Hematologic abnormalities
Severe anemia is more common in children in highly endemic
areas due to repeated or chronic Plasmodium infections.
Thrombocytopenia is common, but usually not associated
with bleeding. Disseminated intravascular coagulation is
reported in fewer than 10% of patients with severe malaria.
Antimalarial treatment of severe malaria
Nonimmune patients with P. falciparum malaria should be
treated as a medical emergency and be considered for hospi-
tal admission, regardless of disease severity at presentation.
All patients with severe malaria (Table 1) and those who are
unable to tolerate drugs orally should initially receive par-
enteral treatment immediately (Table 2) and be admitted to
the ICU [8]. In these patients, gastrointestinal intolerance and
erratic intestinal absorption make the oral route of administra-
tion unreliable. To prevent medication errors it is important to
check whether the recommended dose relates to a base or
salt. Patients with severe malaria should always receive a full
treatment dose, including those with breakthrough malaria
and those who received some prior antimalarial medication.
Monitoring treatment response
When reliable blood smear results are not immediately avail-
able and malaria is suspected on clinical grounds, empiric
treatment for falciparum malaria should be administered
without delay. Treatment response should be assessed by
parasite count daily until clearance of all trophozoites is
achieved. Parasitemia may rise during the first 12–24 hours,
because available drugs do not inhibit schizont rupture and
release of merozoites. Rising parasitemia beyond 36–48
hours after the start of antimalarial treatment indicates treat-
ment failure, usually because of high-level drug resistance
[30]. Because nonimmune hosts may exhibit a high pretreat-
ment total parasite burden (up to 1012 parasites), it may take
up to 6 days to achieve complete elimination of P. falciparum
trophozoites from the blood, even with fast-acting antimalarial
agents (e.g. quinine, artemisinin derivatives). A rising gameto-
cyte count does not indicate treatment failure. Persons with
partial immunity can tolerate low parasitemia (<10000 para-
sites/µl) without clinical symptoms [19]. Therefore, in a pro-
portion of semi-immune individuals parasitemia may not be
responsible for current signs and symptoms [6]. In 5–10% of
patients with falciparum malaria, treatment failure will occur,
with recurrence of symptoms usually within 1 month of treat-
ment. A repeated blood smear examination at 7 and 28 days
after completion of therapy is recommended to monitor for
relapse of severe falciparum malaria [31].
Quinine and quinidine
Intravenous quinine is currently the most widely used agent in
the treatment of severe falciparum malaria, usually formulated
as a dihydrochloride salt. In the USA, quinidine gluconate (the
dextrorotatory optical diastereoisomer of quinine) is the only
available intravenous antimalarial agent, and it may be used
instead of quinine [32]. Quinidine has a twofold to threefold
greater antimalarial activity than does quinine, but it is also
more cardiotoxic and mandates electrocardiographic monitor-
ing [33]. Therefore, most authors prefer quinine over quini-
dine for the treatment of severe malaria. Both quinine and
quinidine may cause cinchonism (bitter taste, dysphoria,
tremor, tinnitus, reversible high-tone hearing loss, headache,
nausea, vomiting, and abdominal pain) or pruritus, which
should not lead to dose reduction. Both drugs have narrow
therapeutic windows. Severe toxicities include cardiac
arrhythmias, hypotension, blindness, deafness, and hyper-
insulinemic hypoglycemia [12,34].
An initial loading dose of quinine or quinidine should be
administered as soon as possible, followed by the mainte-
nance dose. Both drugs should be given by a rate-controlled
intravenous infusion (infusion pump), and never by a bolus
injection, which may cause fatal hypotension or cardiac
arrhythmia. Without a loading dose, it takes more than
24 hours to achieve therapeutic drug concentration. This
delay may allow sequestration of trophozoites causing major
organ dysfunction. The loading dose should not be adminis-
tered to patients who received quinine, quinidine, halo-
fantrine, or mefloquine within the preceding 12 hours. If
intravenous treatment is continued past 48 hours, the mainte-
nance dose should be reduced by 30–50%. In renal failure
(clearance <10ml/min) and in dialysis patients a normal
loading dose should be administered, but the maintenance
dose should be reduced by 30–50%. If hemodialysis is per-
formed, quinine or quinidine should be administered after
dialysis. Electrocardiographic monitoring is mandatory with
quinidine infusion and with quinine infusion if the patient has
acute renal failure. If the QRS complex lengthens by more
than 25% beyond baseline or the QTc interval increases to
more than 500 ms, the infusion should be slowed or discon-
tinued. Monitoring of plasma quinine concentrations does not
predict cardiotoxicity; electrocardiography may be a more
accurate approach for monitoring cardiotoxicity [35]. Thera-
peutic plasma concentration for quinine ranges from 8 to
20mg/l measuring the total (protein bound and free) drug.
Free (unbound) quinine level is more reliable for therapeutic
monitoring than total drug concentration and should be
1–2mg/l. For quinidine the total therapeutic plasma concen-
tration is between 4 to 8mg/l [33]. Apart from lengthening of
the QTc interval, common electrocardiographic abnormalities
include supraventricular and ventricular ectopic beats, sinus
bradycardia (<50 beats/min), and ventricular tachycardia [36].
Artemisinin derivatives
Although artemisinin derivatives clear parasites from blood
about 20% faster than quinine dihydrochloride, improved sur-
vival was observed only in regions of South East Asia with
recognized quinine resistance [37]. Furthermore, recovery
from coma may be delayed and the incidence of seizures was
higher than with quinine dihydrochloride [12,38,39]. At
present, artemisinin derivatives are recommended for treat-
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ment of quinine-resistant P. falciparum infections, combined
with mefloquine, doxycycline, or clindamycin to prevent
recrudescence. There are four artemisinin formulations: dihy-
droartemisinin, artesunate (a water-soluble compound for intra-
muscular injection), arteether, and artemether (an oil-soluble
compound for intravenous injection). Artesunate and
artemether are metabolized to the biologically active metabolite
dihydroartemisinin. Artemisinin derivatives are well tolerated.
Side effects include nausea, vomiting, pruritus, and fever;
bleeding and cardiac arrhythmias rarely occur. Despite reports
of brainstem neurotoxicity with high doses in animal studies,
this side effect has not been observed in humans to date.
Chloroquine
Parenteral chloroquine is the drug of choice for severe
chloroquine-susceptible  P. falciparum infections (originating
from Central America north of the Panama Canal, Haiti,
Dominican Republic, Argentina, Paraguay, Egypt, Syria,
Turkey, Saudi Arabia, Iraq, Azerbaijan, and Mauritius) and for
those rare cases of life-threatening malaria caused by
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Table 2
Recommended regimens for initial parenteral treatment of severe falciparum malaria
Drug Loading dose1 Maintenance dose Comments
Regimen 1
Quinine dihydrochloride 7 mg salt/kg iv over 30 min 10 mg salt/kg diluted in If hemodialysis is performed, then quinine is
salt (available outside the followed immediately by 10 ml/kg isotonic fluid iv over administered after dialysis. Monitor blood glucose
USA), reconstituted in 5% maintenance dose 4 hours repeated every 8 hours2 because of risk for developing hyperinsulinemic
glucose or normal saline OR hypoglycemia
20 mg salt/kg over 4 hours,
followed 8 hours later by
maintenance dose
PLUS (either concurrently or immediately thereafter)
Doxycycline3 Not required 1.5 mg/kg (usually 100 mg) po Should not be given to pregnant or breast-feeding
or iv every 12 hours for 7 days women or children <8 years old
Regimen 2
Quinidine gluconate 10 mg salt/kg (equivalent to 0.02 mg/kg/min salt (equivalent Electrocardiographic monitoring is mandatory; slow or
(available in the USA), 6.2 mg base/kg) iv infused to 0.0125 mg/kg/min base) stop infusion if QRS lengthens >25% of baseline
reconstituted in normal over 1–2 hours, followed continuous iv infusion2 value or QTc interval >500 ms
saline immediately by maintenance
dose
PLUS (either concurrently or immediately thereafter)
Doxycycline3 Not required Same as above
Regimen 3
Artesunate 2.4 mg/kg iv bolus 1.2 mg/kg iv daily4 Artesunic acid 60 mg is dissolved in 0.6 ml 5%
sodium bicarbonate, diluted to 3–5 ml 5% glucose,
and given immediately by iv bolus injection
PLUS
Mefloquine 15 mg/kg (750 mg) base 10 mg/kg (500 mg) base po Total dose: 1500 mg
po initial dose at 6–8 hours and (if >60 kg)
followed by 5 mg/kg (250 mg)
po at 16 hours
Regimen 4
Artemether 3.2 mg/kg im 1.6 mg/kg im daily4
PLUS
Mefloquine Same as above Same as above
1Loading dose should not be administered to patients who received quinine, quinidine, halofantrine, or mefloquine within the preceding 12 hours.
2Intravenous quinine or quinidine should be given for at least 24 hours but oral antimalarial treatment should be substituted as soon as the patient
is stable and can take oral therapy to complete the treatment course. If intravenous treatment is continued past 48 hours, then the maintenance
dose should be reduced by 30–50%. In renal failure and in dialysis patients, the maintenance dose of quinine should be reduced by 30–50%.
3Clindamycin 5 mg/kg (usually 300 mg) po or iv every 8 hours can be administered if the patient is unable to take doxycycline.
4Parenteral artesunate or artemether should be given for at least 3 days but oral antimalarial treatment should be substituted as soon as the patient
is stable and can take oral therapy to complete the treatment course. im = intramuscularly; iv = intravenously; po, orally.321
P. ovale, P. malariae, and P. vivax (except for infections from
Papua New Guinea, Sumatra, Irian Jaya, Myanmar, Vanuatu,
India, and the Amazon region of Brazil) [40]. Chloroquine may
have a more rapid effect on lowering parasitemia than either
quinine or quinidine, but it also has a more profound hypoten-
sive side effect. Chloroquine should be given by a controlled
intravenous infusion with a loading dose 10mg/kg base over
8 hours, followed immediately by a maintenance dose of
15mg/kg base infused over 24 hours.
Oral treatment
When patients with severe falciparum malaria show signifi-
cant clinical improvement (after at least 24 hours of par-
enteral therapy) and can tolerate tablets, they should be
switched to oral medication (Table 3). The choice of oral anti-
malarials is guided by the susceptibility pattern of the plas-
modia. Combined regimens, such as artemether–lumefantrin
or atovaquone–proguanil, are associated with lower risk for
development of resistance than are mefloquine or quinine.
Higher blood levels are reached when oral antimalarials are
given with or after food intake.
Critical care management
Basic supportive care
The intravascular volume should be maintained at the lowest
level sufficient for adequate systemic perfusion. In hypoten-
sion early use of inotropic support is indicated rather than
overhydration. Negative fluid balance is critical to avoid exac-
erbating acute lung injury, but is balanced against the risk for
precipitating acute renal failure [41]. The patient may need to
be intubated because of impaired consciousness or because
of acute lung injury. Mechanical ventilation with lower tidal
volume improves the clinical outcome [42]. A higher positive
end-expiratory pressure may be needed to maintain optimal
arterial oxygenation. In respiratory acidosis, the plateau pres-
sure should be in excess of 25cm H2O and the ventilator rate
should be increased. Surfactant therapy, inhaled nitric oxide,
and corticosteroids have no effect on survival or duration of
ventilation in patients with ARDS [43,44].
Comatose patients should be placed in a semirecumbent posi-
tion to reduce the risk for aspiration. Serum sodium concentra-
tion, arterial carbon dioxide tension, blood glucose, and arterial
lactate concentration should be monitored frequently. Seizures
should be treated promptly with anticonvulsants, but their pro-
phylactic use is still in dispute [12]. The efficacy of hypertonic
mannitol in treatment of cerebral edema is not proven.
Early institution of renal replacement therapy may avoid the
development of ARDS [45]. Patients with hypotension toler-
ate continuous renal replacement therapy better than conven-
tional intermittent hemodialysis. In addition, a continuous
regulation of body fluid avoids periods of volume overload
and depletion. A meta-analysis involving 13 studies (only
three of which were randomized controlled trials) in which
conventional dialysis was compared with continuous hemofil-
tration showed overall no significant difference in mortality
between groups. However, after adjusting for severity of
illness these authors concluded that continuous renal
replacement therapy was associated with a reduced risk for
death [46]. Acidosis is usually multifactorial in origin, with
causes including tissue hypoxia, liver dysfunction, and
impaired renal handling of bicarbonate [47]. Blood transfu-
sion should be considered if the hematocrit falls below 20%,
but volume overload should be avoided.
Antimicrobial therapy
Bacterial infections often complicate the course of patients
with severe malaria. Common infections include aspiration
pneumonia and sepsis. Parasite factors stimulate the produc-
tion and release of cytokines such as tumor necrosis factor
(TNF)-α and interleukin-1 by macrophages, resulting in fever,
chills, and hyperkinetic hemodynamic changes. The clinical
and laboratory characteristics of severe malaria are similar to
those of sepsis. Therefore, a bacterial infection in a patient
with malaria may not be recognized initially. Repeated micro-
biologic sampling of appropriate body fluids such as blood,
sputum, cerebrospinal fluid, and urine may help to diagnose
and treat a possible infection early.
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Table 3
Recommended oral treatment for severe falciparum malaria after initial parenteral therapy for at least 24 hours when clinical
improvement is evident and the patient can tolerate oral medication
Drug Dose Comments
Artemether/lumefantrin 80 mg arthemeter/480 mg lumefantrin once daily for Well tolerated, faster parasite clearance, but longer fever
3 days resolution time
Atovaquone/proguanil 1000 mg atovaquone/400 mg proguanil at 0, 8, 24, 36, Well tolerated, more effective than mefloquine in treatment
48 and 60 hours of multidrug-resistant falciparum malaria
Mefloquine 15 mg/kg (750 mg) base at 0 hours, followed by Contraindicated in persons with seizure or psychiatric
10 mg/kg (500 mg) base at 6–8 hours, and (if >60 kg) disorders, or with cardiac conduction abnormalities
followed by 5 mg/kg (250 mg) at 16 hours
Quinine (sulfate salt) 10 mg salt/kg (600–650 mg) every 8 hours to complete Side effects include cinchonism and pruritus
7 days of treatment (total duration)322
Exchange blood transfusion and red cell exchange
(erythrocytapheresis)
Death in patients with malaria is related to the level of para-
sitemia, with significant mortality when parasitemia exceeds
5% despite appropriate parenteral antimalarial therapy.
Exchange transfusion may rapidly reduce parasitemia,
decrease the risk for intravascular hemolysis, improve blood
flow, decrease cytokines, and improve oxygen-carrying
capacity. Although there are no sufficiently powered, random-
ized, controlled studies, exchange blood transfusion has been
suggested in patients with severe malaria, especially for
those with hyperparasitemia (>5%) [12]. Some authors rec-
ommend exchange transfusion only in countries with well
equipped and staffed ICUs and safe blood supplies [48].
Published data about the effectiveness of this method is con-
troversial. A meta-analysis involving eight studies [49], in
which groups of patients with severe malaria who received
adjunct exchange transfusion were compared with patients
who received antimalarial chemotherapy alone, found no dif-
ference in survival rates between groups. However, patients
who received transfusions had higher parasitemia and were
much more ill according to WHO criteria for severe malaria.
Cytokines such as TNF-α and interleukin-1 probably con-
tribute to the pathogenesis of severe malaria, and some
authors have suggested that plasma exchange, plasmaphere-
sis, and hemodialysis are effective alternatives to exchange
transfusion [50].
Unproven treatments
Therapy with monoclonal antibodies against TNF-α shortens
the duration of fever, but has no impact on mortality in
patients with severe and complicated malaria, and may
increase morbidity due to neurologic sequelae [51]. Although
corticosteroids were used in the past to treat patients with
cerebral malaria, a controlled trial has shown that they are
harmful. Those who received dexamethasone had a longer
duration of coma and worse outcome than did patients who
received antimalarial chemotherapy alone [24]. Results of
studies of antipyretics, pentoxifylline, hyperimmune serum,
and iron chelators (deferoxamine) have shown no effect on
outcome [52].
Conclusion
Malaria should be included in the differential diagnosis of
every febrile illness in a person with a history of travel to a
malaria-endemic area. Delays in recognition and appropriate
treatment of malaria increase morbidity and mortality. The
major complications of severe malaria include cerebral
malaria, pulmonary edema, acute renal failure, severe anemia,
and/or bleeding. Any of these complications can develop
rapidly and progress to death within hours or days. Light
microscopy of blood smears is the standard method for diag-
nosing malaria, although new and promising nonmicroscopic
diagnostic methods are under development. All patients with
severe malaria should receive parenteral treatment immedi-
ately. Currently, intravenous quinine and quinidine are the
most widely used agents, whereas artemisinin derivatives in
general are recommended for treatment of quinine-resistant
P. falciparum infections. Several Internet websites with addi-
tional and updated information on malaria are listed in the
Appendix.
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Appendix
Internet websites for obtaining additional information on
malaria:
• Centers for Disease Control and Prevention (CDC),
National Center for Infectious Diseases, USA: 
http://www.cdc.gov/travel
• World Health Organization:
http://www.who.int/health_topics/malaria
• Health Canada, Population and Public Health Branch:
www.TravelHealth.gc.ca
• Public Health Laboratory Service, Malaria Reference 
Laboratory at London School of Hygiene and Tropical
Medicine, UK:
http://www.malaria-reference.co.uk
• Swiss Tropical Institute, Switzerland:
http://www.sti.ch
• Safe travel:
http://www.safetravel.ch
• International Society of Travel Medicine:
http://www.istm.org
• Malaria Foundation International: http://www.malaria.org
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